Indomethacin Extended-Release Capsules Recalled for cGMP Deviations
KVK Tech, Inc. is recalling Indomethacin Extended-Release Capsules USP, 75 mg (Lot #18400A) nationwide due to cGMP deviations. The recall affects approximately 9,107 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for cGMP deviations, a manufacturing process deviation. The source text does not report any illnesses, injuries, or confirmed adverse health consequences, making this a precautionary/compliance-based recall typical of Class II classifications without reported harm.
Plain-English summary
KVK Tech, Inc. is recalling Indomethacin Extended-Release Capsules USP, 75 mg, in 100-count bottles (NDC 10702-016-01) due to cGMP (current Good Manufacturing Practices) deviations. The affected lot is #18400A with an expiration date of 7/31/2027. Approximately 9,107 bottles were distributed nationwide.
This is a voluntary recall initiated by the manufacturer on May 9, 2025, following notification to the FDA. The FDA classified this as a Class II recall.
Patients taking this medication should not stop taking their indomethacin without consulting their healthcare provider. Consumers with bottles from the affected lot should contact their pharmacist or healthcare provider for further guidance or replacement product.
The recalled product
- Product
- INDOMETHACIN (INDOMETHACIN)
- Brand
- INDOMETHACIN
- Manufacturer
- KVK Tech, Inc.
- Hazard
- Affected units
- 9,107
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 18400A
- Exp 7/31/2027
UPCs (2)
- 0310702016101
- 0310702016033
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by KVK Tech, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · INDOMETHACIN
- ModerateIndomethacin Extended-Release Capsules recalled for cGMP deviations
FDA (Drugs) · 2025-06-11
- ModerateGlenmark Pharmaceuticals Recalls Indomethacin Capsules for Manufacturing Deviations
FDA (Drugs) · 2025-04-16
- ModerateIndomethacin Extended-Release Capsules Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2024-09-04
- HighPrescription Drug Indomethacin Recalled Due to Label Mix-Up
FDA (Drugs) · 2023-12-06
- ModerateHetero Labs Recalls Indomethacin Capsules Due to Deformed or Clumped Units
FDA (Drugs) · 2018-08-08
Same manufacturer · KVK Tech, Inc.
See all →- ModeratePhentermine Hydrochloride Capsules 30mg Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-28
- SevereBetaxolol Hydrochloride tablets recalled due to oxycodone contamination
FDA (Drugs) · 2023-10-25
- SevereAtovaquone Oral Suspension Recalled for Temperature Abuse
FDA (Drugs) · 2021-09-01
- ModerateKVK-Tech Recalls Hydrocodone and Homatropine Tablets for Impurity Failures
FDA (Drugs) · 2021-05-26
- LowKVK-Tech Recalls Benzhydrocodone and Acetaminophen Tablets Due to Impurity
FDA (Drugs) · 2021-01-20
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19